111 related articles for article (PubMed ID: 38218560)
21. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G;
Cancer; 2004 Nov; 101(9):2067-78. PubMed ID: 15372475
[TBL] [Abstract][Full Text] [Related]
22. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry.
Leiter U; Buettner PG; Eigentler TK; Bröcker EB; Voit C; Gollnick H; Marsch W; Wollina U; Meier F; Garbe C
J Am Acad Dermatol; 2012 Jan; 66(1):37-45. PubMed ID: 21700361
[TBL] [Abstract][Full Text] [Related]
23. Loss in Life Expectancy After Surgical Aortic Valve Replacement: SWEDEHEART Study.
Glaser N; Persson M; Jackson V; Holzmann MJ; Franco-Cereceda A; Sartipy U
J Am Coll Cardiol; 2019 Jul; 74(1):26-33. PubMed ID: 31272548
[TBL] [Abstract][Full Text] [Related]
24. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
26. A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma.
Hynes MC; Nguyen P; Groome PA; Asai Y; Mavor ME; Baetz TD; Hanna TP
BMC Cancer; 2022 Jul; 22(1):720. PubMed ID: 35778691
[TBL] [Abstract][Full Text] [Related]
27. Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
Vikström S; Mikiver R; Lapins J; Nielsen K; Vassilaki I; Lyth J; Isaksson K; Eriksson H
Br J Dermatol; 2023 Nov; 189(6):702-709. PubMed ID: 37463416
[TBL] [Abstract][Full Text] [Related]
28. Patients with Limited Life Expectancy Are Biopsied for Keratinocyte Cancers at Similar Frequency to Healthy Patients.
Chen HW; Coias J; Walker AM; Prasad S; Ma L; Hynan LS; Jacobe H
Dermatology; 2023; 239(4):565-571. PubMed ID: 36921586
[TBL] [Abstract][Full Text] [Related]
29. Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
Johannet P; Simons M; Qian Y; Azmy N; Mehnert JM; Weber JS; Zhong J; Osman I
Cancer; 2022 Oct; 128(20):3620-3629. PubMed ID: 36006879
[TBL] [Abstract][Full Text] [Related]
30. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
Utjés D; Malmstedt J; Teras J; Drzewiecki K; Gullestad HP; Ingvar C; Eriksson H; Gillgren P
Lancet; 2019 Aug; 394(10197):471-477. PubMed ID: 31280965
[TBL] [Abstract][Full Text] [Related]
31. Life expectancy and expected years of life lost to oral cancer in Taiwan: a nation-wide analysis of 22,024 cases followed for 10 years.
Huang CC; Ou CY; Lee WT; Hsiao JR; Tsai ST; Wang JD
Oral Oncol; 2015 Apr; 51(4):349-54. PubMed ID: 25604257
[TBL] [Abstract][Full Text] [Related]
32. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society.
Buettner PG; Leiter U; Eigentler TK; Garbe C
Cancer; 2005 Feb; 103(3):616-24. PubMed ID: 15630700
[TBL] [Abstract][Full Text] [Related]
33. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A
Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589
[TBL] [Abstract][Full Text] [Related]
34. Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study.
Barreiro-Capurro A; Andrés-Lencina JJ; Podlipnik S; Carrera C; Requena C; Manrique-Silva E; Quaglino P; Tonella L; Jaka A; Richarz N; Rodríguez-Peralto JL; Ortiz P; Boada A; Ribero S; Nagore E; Malvehy J; Puig S
Eur J Cancer; 2021 Mar; 145():29-37. PubMed ID: 33418234
[TBL] [Abstract][Full Text] [Related]
35. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
37. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients.
Sigalotti L; Fratta E; Bidoli E; Covre A; Parisi G; Colizzi F; Coral S; Massarut S; Kirkwood JM; Maio M
J Transl Med; 2011 May; 9():78. PubMed ID: 21615918
[TBL] [Abstract][Full Text] [Related]
38. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
Ishihara K; Saida T; Otsuka F; Yamazaki N;
Int J Clin Oncol; 2008 Feb; 13(1):33-41. PubMed ID: 18307017
[TBL] [Abstract][Full Text] [Related]
39. Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma.
Leeneman B; Franken MG; Coupé VMH; Hendriks MP; Kruit W; Plaisier PW; van Ruth S; Verstijnen JAMC; Wouters MWJM; Blommestein HM; Uyl-de Groot CA
Eur J Surg Oncol; 2019 May; 45(5):825-831. PubMed ID: 30765270
[TBL] [Abstract][Full Text] [Related]
40. A simplified estimation of loss of life expectancy (LLE) using rectangular approximation method.
Watanabe N; Mizutani S; Takatsuki H
Environ Sci; 2007; 14(1):9-14. PubMed ID: 17450116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
